Comparing treatment outcomes of concurrent chemoradiotherapy with or without nimotuzumab in patients with locoregionally advanced nasopharyngeal carcinoma

References

• Ferlay J, Bray F, Pisani P, Parkin DM. Cancer incidence, mortality and prevalence worldwide. 2.0. Lyon: IARC Press; 2004.
   Google Scholar
• Torr e LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65:87–108. doi:10.3322/caac.21262.
   PubMed Web of Science ®Google Scholar
• Li WF, Sun Y, Chen M, Tang LL, Liu LZ, Mao YP, Chen L, Zhou GQ, Li L, Ma J. Locoregional extension patterns of nasopharyngeal carcinoma and suggestions for clinical target volume delineation. Chin J Cancer. 2012;31(12):579–587. doi:10.5732/cjc.012.10095.
   PubMed Web of Science ®Google Scholar
• Internet National Comprehensive Cancer Network. NCCN Guidelines: head and neck cancers; Version 2.2013. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
   Google Scholar
• Lee AW, Sze WM, Au JS, Leung SF, Leung TW, Chua DT, Zee BC, Law SC, Teo PM, Tung SY, et al. Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience. Int J Radiat Oncol Biol Phys. 2005; 61:1107–1116. doi:10.1016/j.ijrobp.2004.07.702.
   PubMed Web of Science ®Google Scholar
• Ma BB, Hui EP, Chan AT. Systemic approach to improving treatment outcome in nasopharyngeal carcinoma: current and future directions. Cancer Sci. 2008;99(7):1311–1318. doi:10.1111/j.1349-7006.
   PubMed Web of Science ®Google Scholar
• Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res. 2001; 7:2958–2970.
   PubMed Web of Science ®Google Scholar
• Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol. 2002; 20:1S–13S.
   PubMed Web of Science ®Google Scholar
• Zhang P, Wu SK, Wang Y, Fan ZX, Li CR, Feng M, Xu P, Wang WD, Lang JY. p53, MDM2, eIF4E and EGFR expression in nasopharyngeal carcinoma and their correlation with clinicopathological characteristics and prognosis: A retrospective study. Oncology Letters. 2015; 9:113–118. doi:10.3892/ol.2014.2631.
   PubMed Web of Science ®Google Scholar
• Ang KK, Zhang Q, Rosenthal DI, Nguyen-Tan PF, Sherman EJ, Weber RS, Galvin JM, Bonner JA, Harris J, El-Naggar AK, et al. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol. 2014;32(27):2940–2950. doi:10.1200/JCO.2013.53.5633.
   PubMed Web of Science ®Google Scholar
• Talavera A, Friemann R, Gómez-Puerta S, Martinez-Fleites C, Garrido G, Rabasa A, López-Requena A, Pupo A, Johansen RF, Sánchez O, et al. Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation. Cancer Research. 2009; 69:5851–5859. doi:10.1158/0008-5472.CAN-08-4518.
   PubMed Web of Science ®Google Scholar
• Huang JF, Zhang FZ, Zou QZ, Zhou LY, Yang B, Chu JJ, Yu JH, Zhang HW, Yuan XP, Tai GM, et al. Induction chemotherapy followed by concurrent chemoradiation and nimotuzumab for locoregionally advanced nasopharyngeal carcinoma: preliminary results from a phase II clinical trial. Oncotarget. 2017;8(2):2457–2465. doi:10.18632/oncotarget.13899.
   PubMedGoogle Scholar
• Yao JJ, Yu XL, Zhang F, Zhang WJ, Zhou GQ, Tang LL, Mao YP, Chen L, Ma J, Sun Y. Radiotherapy with neoadjuvant chemotherapy versus concurrent chemoradiotherapy for ascending-type nasopharyngeal carcinoma: a retrospective comparison of toxicity and prognosis. Chin J Cancer. 2017;36(1):26. doi:10.1186/s40880-017-0195-6.
   PubMedGoogle Scholar
• ICRU report. Vol. 62: prescribing, recording, and reporting photon beam therapy. Maryland: International Commission on Radiation Units and Measurements; 1999.
   Google Scholar
• ICRU Report. Vol. 83: prescribing, Recording, and Reporting Photon-Beam Intensity-Modulated Radiation Therapy (IMRT). Maryland: International Commission on Radiation Units and Measurements; 2010.
   Google Scholar
• D’Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998; 17:2265–2281. doi:10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B.
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc. 1958; 53:457–481. doi:10.1080/01621459.1958.10501452.
   Web of Science ®Google Scholar
• Cox DR. Regression models and life tables. J Roy Stat Soc B. 1972; 34:187–220.
   Web of Science ®Google Scholar
• Ma X, Huang J, Wu X, Li X, Zhang J, Xue L, Li P, Liu L. Epidermal growth factor receptor could play a prognostic role to predict the outcome of nasopharyngeal carcinoma: A meta-analysis. Cancer Biomark. 2014;14(4):267–277. doi:10.3233/CBM-140401.
   PubMed Web of Science ®Google Scholar
• Sun W, Long G, Wang J, Mei Q, Liu D, Hu G. Prognostic role of epidermal growth factor receptor in nasopharyngeal carcinoma: a meta-analysis. Head Neck. 2014;36(10):1508–1516. doi:10.1002/hed.23481.
   PubMed Web of Science ®Google Scholar
• Liu ZG, Zhao Y, Tang J, Zhou YJ, Yang WJ, Qiu YF, Wang H. Nimotuzumab combined with concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a retrospective analysis. Oncotarget. 2016;7(17):24429–24435. doi:10.18632/oncotarget.8225.
   PubMedGoogle Scholar
• Peng G, Wang T, Yang KY, Zhang S, Zhang T, Li Q, Han J, Wu G. A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma. Radiother Oncol. 2012;104(3):286–293. doi:10.1016/j.radonc.
   PubMed Web of Science ®Google Scholar
• Zhang MX, Li J, Shen GP, Zou X, Xu JJ, Jiang R, You R, Hua YJ, Sun Y, Ma J, et al. Intensity-modulated radiotherapy prolongs the survival of patients with nasopharyngeal carcinoma compared with conventional two-dimensional radiotherapy: A 10-year experience with a large cohort and long follow-up. Eur J Cancer. 2015;51(17):2587–2595. doi:10.1016/j.ejca.2015.08.006.
   PubMed Web of Science ®Google Scholar
• Lee N, Harris J, Garden AS, Straube W, Glisson B, Xia P, Bosch W, Morrison WH, Quivey J, Thorstad W, et al. Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225. J Clin Oncol. 2009;27(22):3684–3690. doi:10.1200/JCO.2008.19.9109.
   PubMed Web of Science ®Google Scholar
• Lee N, Xia P, Quivey JM, Sultanem K, Poon I, Akazawa C, Akazawa P, Weinberg V, Fu KK. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys. 2002;53(1):12–22.
   PubMed Web of Science ®Google Scholar
• Aw L, Wh L, Sy T, Dt C, Chappell R, Xu L, Siu L, Wm S, Tw L, Js S, et al., Nasopharyngeal Cancer Study Group. Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group. J Clin Oncol. 2005; 23: 6966–6975. doi:10.1200/JCO.2004.00.7542.
   PubMed Web of Science ®Google Scholar
• Blanchard P, Lee A, Marguet S, Leclercq J, Wt N, Ma J, At C, Py H, Benhamou E, Zhu G, et al., MAC-NPC Collaborative Group. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. Lancet Oncol. 2015;16(6):645–655. doi:10.1016/S1470-2045(15)70126-9.
   PubMed Web of Science ®Google Scholar
• Lin JC, Wang WY, Chen KY, Wei YH, Liang WM, Jan JS, Jiang RS. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med. 2004;350(24):2461–2470. doi:10.1056/NEJMoa032260.
   PubMed Web of Science ®Google Scholar
• Lo YM, Chan AT, Chan LY, Leung SF, Lam CW, Huang DP, Johnson PJ. Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA. Cancer Res. 2000;60(24):6878–6881.
   PubMed Web of Science ®Google Scholar